Patent intelligence · WO
WO 2025252204
DISPERSIONS SOLIDES AMORPHES D'UN INHIBITEUR DE BRAF
DISPERSIONS SOLIDES AMORPHES D'UN INHIBITEUR DE BRAF
Patent details — WO 2025252204
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Dec 11, 2025
- Expiration
- Dec 6, 2045
- Applicant
- BEIGENE SUZHOU CO LTD [CN]
- CPC classes
- A61K 9/ 00 A I, A61K 31/ 4375 A I, A61K 47/ 34 A I, A61K 47/ 38 A I
Quick answer
WO 2025252204 (DISPERSIONS SOLIDES AMORPHES D'UN INHIBITEUR DE BRAF) is held by BEIGENE SUZHOU CO LTD [CN]. Status: granted. Granted Dec 11, 2025. Expires Dec 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BEIGENE SUZHOU CO LTD [CN]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 31/ 4375 A I, A61K 47/ 34 A I, A61K 47/ 38 A I, A61K/314375, A61K/4732
More from BEIGENE SUZHOU CO LTD [CN]
Related pharmaceutical patents in our USPTO index.
-
AU 2025242171
A Medicament and Method of Treatment of Central Nervous System and/or Neuropsychiatric Disorders
granted -
WO 2025232885
PROCÉDÉ DE PRÉPARATION D'UN AGENT DE DÉGRADATION DE LA TYROSINE KINASE DE BRUTON
granted -
WO 2025218772
FORMES SOLIDES COMPRENANT UN AGENT DE DÉGRADATION DE TYROSINE KINASE DE BRUTON ET LEURS UTILISATIONS
granted -
WO 2025214466
CONJUGUÉS DE PYRROLOBENZODIAZÉPINE CIBLÉS
granted -
WO 2025201453
COMPOSÉS MACROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE RAS
granted -
US 2025304535
KAT6 Inhibitors
granted -
US 2025290040
GAMMA DELTA T CELL COMPOSITIONS AND METHODS OF USE
granted
Frequently asked questions
What is US patent 2025252204?
WO 2025252204 (DISPERSIONS SOLIDES AMORPHES D'UN INHIBITEUR DE BRAF) is held by BEIGENE SUZHOU CO LTD [CN]. Status: granted. Granted Dec 11, 2025. Expires Dec 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2025252204?
BEIGENE SUZHOU CO LTD [CN] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2025252204 expire?
Our index shows an expiration date of Dec 6, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.